** Shares of California-based diagnostic firm Bio-Rad BIO.N down 8.25% at $281.10
** Co reports Q4 sales of $667.5 million, missing analysts' estimate of $679.3 million, according to data compiled by LSEG
** Expects 2025 revenue growth of about 1.5% to 3.5% and operating margin of ~13% to 13.5%
** The forecast is mixed, as core growth bracketed expectations, but margins disappointed - Jefferies
** Co says will lay off about 5% of its workforce as a part of its restructuring plan - filing
** Adds will incur between about $45 million and $50 million in costs
** It reported Q4. adj profit of $2.9 vs est. $2.87
** In the last 12 months, the stock has fallen ~15%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.